• Identification of CYP24 single nucleotide polymorphisms (SNPs) [ Designated as safety issue: No ]
  
• Effect of CYP24 SNPs on baseline serum vitamin D3 metabolites (25-D3, 24,25-D3, and 1,25-D3), and parathyroid hormone levels (PTH) [ Designated as safety issue: No ]
  
• Effect of CYP24 SNPs on serum vitamin D3 metabolites and PTH levels during cholecalciferol treatment [ Designated as safety issue: No ]
  
• CYP24 splicing, protein expression, and enzyme activity at baseline and during cholecalciferol treatment [ Designated as safety issue: No ]
  
• Relationship between serum cholecalciferol pharmacokinetic parameters and CYP24 SNPs, splicing variants, and enzyme activity [ Designated as safety issue: No ]
  

OBJECTIVES:

• To identify CYP24 single nucleotide polymorphisms (SNPs) using peripheral blood mononuclear cell genomic DNA from patients with colorectal cancer receiving cholecalciferol supplementation.
• To evaluate the effects of these CYP24 SNPs on baseline serum vitamin D_3 metabolites (25-D_3, 24,25-D_3, and 1,25-D_3), and parathyroid hormone levels (PTH).
• To evaluate the effects of these CYP24 SNPs on serum vitamin D_3 metabolites and PTH levels during cholecalciferol treatment.
• To examine CYP24 splicing, protein expression, and enzyme activity at baseline and during cholecalciferol treatment.
• To determine the relationship, if any, between serum cholecalciferol pharmacokinetic parameters and CYP24 SNPs, splicing variants, and enzyme activity.

OUTLINE: Patients receive oral cholecalciferol 2000 IU once daily for 1 year. Patients without response to vitamin D supplementation (serum 25-D_3 level < 32 ng/mL) by 6 months will have their cholecalciferol dose increased to 4000 IU once daily.

Blood is collected at baseline and on days 14, 30, 60, 90, 180, 270, and 360. Peripheral blood mononuclear cells for CYP24 genotyping, protein expression, enzyme activity, and splicing variants are analyzed by polymerase chain reaction (PCR), western blot, high performance liquid chromatography, and reverse transcriptase PCR, respectively. Serum is analyzed for vitamin D_3 metabolite levels (by radioimmunoassay), calcium (to monitor for hypercalcemia), and parathyroid hormone assays (to measure vitamin D effect).

DISEASE CHARACTERISTICS:

• Prior or current documented diagnosis of colorectal cancer

  • All stages
• 25OH-D3 level < 50 ng/mL

PATIENT CHARACTERISTICS:

• ECOG performance status 0-2
• Life expectancy > 6 months
• Serum creatinine < 2.0 mg/dL
• Serum bilirubin < 2.0 mg/dL
• No prior or current hypercalcemia (defined as albumin corrected serum calcium < 10.2 mg/dL)
• No known contraindication for vitamin D supplementation
• No genitourinary stones within the past 5 years
• No severe comorbid conditions such as uncompensated heart failure or active infection

PRIOR CONCURRENT THERAPY:

• No supplemental vitamin D beyond what is provided through the study

• At least 2 months since prior vitamin D supplementation exceeding 800 International Units (IU)

  • Nondietary vitamin D supplements should not have exceeded 800 IU/day within the past 2 months